Malaga Cove Capital LLC Acquires Shares of 7,732 Pacira Pharmaceuticals, Inc. (PCRX)

Malaga Cove Capital LLC purchased a new stake in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) during the second quarter, according to its most recent filing with the SEC. The institutional investor purchased 7,732 shares of the company’s stock, valued at approximately $373,000.

A number of other institutional investors have also modified their holdings of the company. BlackRock Inc. increased its position in shares of Pacira Pharmaceuticals by 28,922.7% in the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock worth $145,180,000 after buying an additional 3,172,817 shares during the period. Vanguard Group Inc. raised its position in Pacira Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 2,860,092 shares of the company’s stock valued at $130,420,000 after buying an additional 112,853 shares in the last quarter. Westfield Capital Management Co. LP raised its position in Pacira Pharmaceuticals by 0.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,608,847 shares of the company’s stock valued at $73,363,000 after buying an additional 5,166 shares in the last quarter. State Street Corp raised its position in Pacira Pharmaceuticals by 2.7% in the first quarter. State Street Corp now owns 1,107,356 shares of the company’s stock valued at $50,499,000 after buying an additional 28,663 shares in the last quarter. Finally, Macquarie Group Ltd. raised its position in Pacira Pharmaceuticals by 6.7% in the first quarter. Macquarie Group Ltd. now owns 1,074,770 shares of the company’s stock valued at $49,010,000 after buying an additional 67,321 shares in the last quarter.

Pacira Pharmaceuticals, Inc. (PCRX) traded up 0.27% during mid-day trading on Wednesday, hitting $37.15. 633,459 shares of the stock traded hands. The firm’s 50-day moving average is $43.76 and its 200-day moving average is $45.31. Pacira Pharmaceuticals, Inc. has a 12-month low of $29.95 and a 12-month high of $58.95. The company’s market cap is $1.50 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The firm had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. During the same period in the prior year, the company posted $0.21 earnings per share. Pacira Pharmaceuticals’s quarterly revenue was up 1.9% compared to the same quarter last year. Equities research analysts expect that Pacira Pharmaceuticals, Inc. will post ($0.05) EPS for the current year.

WARNING: “Malaga Cove Capital LLC Acquires Shares of 7,732 Pacira Pharmaceuticals, Inc. (PCRX)” was first reported by BBNS and is the property of of BBNS. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/malaga-cove-capital-llc-takes-position-in-pacira-pharmaceuticals-inc-pcrx-updated-updated-updated/1254095.html.

Several equities analysts have issued reports on PCRX shares. Wedbush reaffirmed an “outperform” rating and issued a $89.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, April 19th. Mizuho reissued a “buy” rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Canaccord Genuity set a $60.00 target price on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 22nd. Royal Bank Of Canada set a $58.00 target price on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, July 30th. Finally, Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $54.50.

In other news, CEO David M. Stack sold 4,311 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $186,752.52. Following the completion of the sale, the chief executive officer now directly owns 59,559 shares of the company’s stock, valued at $2,580,095.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Lauren Bullaro Riker sold 601 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $43.32, for a total transaction of $26,035.32. The disclosure for this sale can be found here. Insiders have sold 9,523 shares of company stock valued at $412,536 over the last ninety days. Insiders own 6.60% of the company’s stock.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.